Amedica (NASDAQ:AMDA) Receives Daily News Impact Score of 0.22

Media stories about Amedica (NASDAQ:AMDA) have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amedica earned a news impact score of 0.22 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 45.0610035170795 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

AMDA opened at $1.40 on Friday. The stock has a market capitalization of $6.24, a PE ratio of -0.10 and a beta of -1.13. Amedica has a 12 month low of $1.32 and a 12 month high of $6.96.

Several equities research analysts have issued reports on the company. Maxim Group reaffirmed a “hold” rating on shares of Amedica in a research note on Tuesday, March 6th. ValuEngine raised Amedica from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

WARNING: “Amedica (NASDAQ:AMDA) Receives Daily News Impact Score of 0.22” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at

Amedica Company Profile

Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and commercializes a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. The company offers Valeo silicon nitride spinal fusion devices for use in the cervical and thoracolumbar areas of spine; and a line of non-silicon nitride spinal fixation products to address spinal deformity and degenerative conditions.

Insider Buying and Selling by Quarter for Amedica (NASDAQ:AMDA)

Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with's FREE daily email newsletter.

Leave a Reply